Walmsley says GSK is “incredibly intentional” in how the company recruits and trains talent. The company’s management has ...

CEO Emma Walmsley said the company has been anticipating tariffs on the industry and is “confident” the company can navigate through it, Ashleigh Furlong and Ruth David of Bloomberg reports. The U.S.

Explore how U.S. tariffs and vaccine skepticism may impact GSK plc's profitability. Click for my update as tariffs are ...

Ohio Attorney General Dave Yost is pushing to take a leading role in a federal securities lawsuit that accuses pharmaceutical ...

GSK has continued to flesh out its neuroscience strategy with a 2 billion pound sterling ($2.5 billion) deal to use a South ...

ABL Bio has announced a global licensing agreement with GSK, allowing the latter to develop medicines for neurodegenerative ...

Chairman & CEO. “Faisal has a proven track record in integrating cutting-edge science with practical, evidence-base PHILADELPHIA, October 24, 2024--New data for AREXVY, GSK’s RSV vaccine ...

GSK is funding public health organizations working ... Thomas Heymann, President and CEO, Sepsis Alliance, said: “Each year, sepsis kills more people than cancer. Since sepsis results from ...

Programs will leverage ABL Bio's Grabody-B platform technology to deliver molecules across the blood-brain barrier.

Fungi-focused biotech LifeMine Therapeutics is slimming down its staff and consolidating its operations to dig into clinical ...

GSK CEO Emma Walmsley’s $13 million salary is predicated on picking the right people to steer cutting-edge drug development for the world’s most challenging diseases. During her eight years at ...